Results 51 to 60 of about 957 (180)

Biologically Active 1-Arylpiperazines. Synthesis of New N-(4-Aryl-1-piperazinyl)alkyl Derivatives of Quinazolidin-4(3H)-one, 2,3-Dihydrophthalazine-1,4-dione and 1,2-Dihydropyridazine-3,6-dione as Potential Serotonin Receptor Ligands

Molecules, 2001
The synthesis of a series of new n-propyl and n-butyl chain containing 1-arylpiperazine derivatives of quinazolidin-4(3H)-one (7) 2-phenyl-2,3-dihydrophthalazine-1,4-dione (8) and 1-phenyl-1,2-dihydropyridazine-3,6-dione (9) as potential serotonin ...
Sijka Charakchieva-Minol, Andrzej J. Bojarski, Maria J. Mokrosz, Teresa Kowalska, Piotr Kowalski   +4 more
doaj   +1 more source

A NEW SCAFFOLD FOR D3 DOPAMINERGIC AFFINITY CONTAINING ARYLPIPERAZINE FRAGMENT: MOLECULAR MODELING, SYNTHESIS, IN VITRO AND IN VIVO PHARMACOLOGICAL EVALUATION [PDF]

Bulletin of Pharmaceutical Sciences. Assiut University, 2007
A new series of N-(6-substitutedbenzo[d]thiazol-2-yl)-2-(4-arylpiperazin-1-yl) acetamides (3a-f) and 2-(3-(4-arylpiprazin-1-yl)propylthio)benzo[d]thiazoles/-oxazoles/-imidazole (6a-f) wassynthesized by connecting arylpiperazine through a semi-rigid ...
Franziska U. Müller, Dalal Abou El Ella   +1 more
doaj   +1 more source

4-Azatricyclo[5.2.2.02,6]undecane-3,5,8-triones as Potential Pharmacological Agents

Molecules, 2008
A series of twenty six arylpiperazine and aminoalkanol derivatives of 4-azatricyclo[ 5.2.2.02,6]undecane-3,5,8-trione have been prepared. The synthesized compounds were evaluated for their cytotoxicity and anti-HIV-1 activity in MT-4 cells.
Marta Struga, Izabela Dybała, Anna E. Kozioł, Barbara Mirosław, Anna Bielenica, Jerzy Kossakowski   +5 more
doaj   +1 more source

Towards the development of 5-HT7 ligands combining serotonin-like and arylpiperazine moieties

, 2014
Many known 5-HT7 ligands contain either a serotonin-like or an arylpiperazine structure that, in published SAR studies, are generally supposed to bind the same receptor pocket. Conversely, we explored the hypothesis that two such moieties can co-exist in
Riccioni T., Cabri W., PALA, Daniele, Bartolucci S., Mor M., Tarzia G., Borsini F., MOR, Marco, Minetti P., Marzi M., Pala D., Cabri W, Spadoni G., Rivara S., Celona D., RIVARA, Silvia, Bedini A.   +16 more
core   +2 more sources

Piperazine amides with desirable solubility, physicochemical and drug-like properties: Synthesis and evaluation of the anti-Trypanosoma cruzi activity

Saudi Pharmaceutical Journal, 2023
The absence of effective chronic treatment, expansion to non-endemic countries and the significant burden in public health have stimulated the search for novel therapeutic options to treat Chagas disease, a protozoan disease caused by Trypanosoma cruzi ...
Marina T. Varela, Maiara Romanelli, Maiara Amaral, Andre G. Tempone, João Paulo S. Fernandes   +4 more
doaj   +1 more source

A perspective on multi‐target drug discovery and design for complex diseases

Clinical and Translational Medicine, Volume 7, Issue 1, December 2018., 2018
AbstractDiseases of infection, of neurodegeneration (such as Alzheimer's and Parkinson's diseases), and of malignancy (cancers) have complex and varied causative factors. Modern drug discovery has the power to identify potential modulators for multiple targets from millions of compounds.
Rona R. Ramsay, Marija R. Popovic‐Nikolic, Katarina Nikolic, Elisa Uliassi, Maria Laura Bolognesi   +4 more
wiley   +1 more source

Synthesis and Experimental Validation of New Designed Heterocyclic Compounds with Antiproliferative Activity versus Breast Cancer Cell Lines MCF‐7 and MDA‐MB‐231

Journal of Chemistry, Volume 2017, Issue 1, 2017., 2017
Recent drug discovery efforts are highly focused towards identification, design, and synthesis of small molecules as anticancer agents. With this aim, we recently designed and synthesized novel compounds with high efficacy and specificity for the treatment of breast tumors.
Vincenza Barresi, Carmela Bonaccorso, Domenico A. Cristaldi, Maria N. Modica, Nicolò Musso, Valeria Pittalà, Loredana Salerno, Cosimo G. Fortuna, Oliver Sutcliffe   +8 more
wiley   +1 more source

Design, Synthesis and 5-HT_1A Binding Affinity of N-(3-(4-(2-Methoxyphenyl)piperazin-1-yl)propyl)tricyclo[3.3.1.1^3,7]decan-1-amine and N-(3-(4-(2-Methoxyphenyl)piperazin-1-yl)propyl)-3,5-dimethyl-tricylo[3.3.1.1^3,7]decan-1-amine

Molbank, 2022
Based on previously highlighted structural features, the development of highly selective 5-HT1A receptor inhibitors is closely linked to the incorporation of a 4-alkyl-1-arylpiperazine scaffold on them.
Grigoris Zoidis, María Isabel Loza, Marco Catto   +2 more
doaj   +1 more source

5‐HT2A receptor agonism by tert‐leucinamide and valinamide synthetic cannabinoids: In vitro and in vivo evidence

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose New synthetic cannabinoid receptor agonists (SCRAs) are associated with severe adverse effects, including unexpected psychiatric symptoms. These compounds are mainly active through their potent agonism on the cannabinoid receptors CB1 and CB2.
Giorgia Corli, Deborah Rudin, Dino Luethi, Matthias E. Liechti, Sabrine Bilel, Matteo Marti, Henrik Green, Manuela Carla Monti, Caitlyn Norman   +8 more
wiley   +1 more source

Synthesis and Structural Activity Relationship Study of Antitubercular Carboxamides

International Journal of Medicinal Chemistry, Volume 2014, Issue 1, 2014., 2014
The unusual structure and chemical composition of the mycobacterial cell wall, the tedious duration of therapy, and resistance developed by the microorganism have made the recurrence of the disease multidrug resistance and extensive or extreme drug resistance.
D. I. Ugwu, B. E. Ezema, F. U. Eze, D. I. Ugwuja, Arie Zask   +4 more
wiley   +1 more source